EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Read-Gene's enterprise value is zł57.81 Mil.
Read-Gene's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was zł8.66 Mil. Therefore, Read-Gene's EV-to-Revenue for today is 6.68.
The historical rank and industry rank for Read-Gene's EV-to-Revenue or its related term are showing as below:
WAR:RDG'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.09 Med: 3.9 Max: 115.95
Current: 6.68
During the past 13 years, the highest EV-to-Revenue of Read-Gene was 115.95. The lowest was 0.09. And the median was 3.90.
WAR:RDG's EV-to-Revenue is ranked better than 54.43% of 1038
companies
in the Biotechnology industry
Industry Median: 7.97
vs WAR:RDG: 6.68
As of today (2024-05-15), Read-Gene's stock price is zł5.10.
Read-Gene's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was zł0.74. Therefore, Read-Gene's PS Ratio for today is 6.94.
Read-Gene EV-to-Revenue Historical Data
The historical data trend for Read-Gene's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Read-Gene's EV-to-Revenue
For the Biotechnology subindustry, Read-Gene's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Read-Gene's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Read-Gene's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Read-Gene's EV-to-Revenue falls into.
Read-Gene's current Enterprise Value is zł57.81 Mil.
Read-Gene's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł8.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Read-Gene's share price for today is zł5.10.
Read-Gene's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.74.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Read-Gene EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Read-Gene's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WAR:RDG has been successfully added to your 